Table 5.
Clinical outcomes in rosuvastatin trial
| Outcomes | Rosuvastatin (N = 18) | Placebo (N = 16) | HR (95% CI) |
|---|---|---|---|
| Composite of all-cause mortality or non-fatal myocardial infarction within 30 days after surgery, n (%) | 1 (5.6) | 0 (0.0) | –a |
| All-cause mortality, n (%) | 0 (0.0) | 0 (0.0) | |
| Non-fatal myocardial infarction, n (%) | 1 (5.6%) | 0 (0.0%) | |
| Myocardial infarction, n (%) | 1 (5.6%) | 0 (0.0%) | –a |
| MINS, n (%) | 2 (11.1) | 2 (12.5%) | 0.92 (0.13–6.64) |
| Cardiac revascularization, n (%) | 0 (0.0) | 0 (0.0) | –a |
| Venous thromboembolism, n (%) | 0 (0.0) | 0 (0.0) | –a |
| Postoperative infection, n (%) | 4 (22.2) | 1 (6.3) | 3.36 (0.37–30.4) |
| Postoperative sepsis, n (%) | 2 (11.1) | 0 (0.0) | –a |
| Congestive heart failure, n (%) | 0 (0.0) | 0 (0.0) | –a |
| Re-hospitalization for vascular reason, n (%) | 0 (0.0) | 0 (0.0) | –a |
| Statin-induced myopathy, n (%) | 0 (0.0) | 0 (0.0) | –a |
TXA tranexamic acid, HR hazard ratio, CI confidence interval, MINS myocardial injury after noncardiac surgery
aNot determinable